Section 21
Chapter 20,638

A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model

Li, G.; Andreansky, S.; Helguera, G.; Sepassi, M.; Janikashvili, N.; Cantrell, J.; Lacasse, C.L.; Larmonier, N.; Penichet, M.L.; Katsanis, E.

Molecular Cancer Therapeutics 7(3): 721-729


ISSN/ISBN: 1535-7163
PMID: 18347157
DOI: 10.1158/1535-7163.mct-07-2067
Accession: 020637339

Download citation:  

We have documented previously that a multiple chaperone protein vaccine termed chaperone-rich cell lysate (CRCL) promotes tumor-specific T-cell responses leading to cancer regression in several mouse tumor models. We report here that CRCL vaccine generated from a mouse breast cancer (TUBO, HER2/neu positive) is also capable of eliciting humoral immunity. Administration of TUBO CRCL triggered anti-HER2/neu antibody production and delayed the progression of established tumors. This antitumor activity can be transferred through the serum isolated from TUBO CRCL-immunized animals and involved both B cells and CD4(+) T lymphocytes. Further evaluation of the mechanisms underlying TUBO CRCL-mediated humoral immunity highlighted the role of antibody-dependent cell-mediated cytotoxicity. These results suggest that tumor-derived CRCL vaccine has a wider applicability as a cancer vaccine because it can target both T-cell- and B-cell-specific responses and may represent a promising approach for the immunotherapy of cancer.

PDF emailed within 0-6 h: $19.90